Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Apple Inc. (AAPL) - free report >>
Adaptimmune Therapeutics PLC (ADAP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apple Inc. (AAPL) - free report >>
Adaptimmune Therapeutics PLC (ADAP) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for January 22nd
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:
Apple Inc. (AAPL - Free Report) : This manufacturer of smartphones has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
Apple Inc. Price and Consensus
Apple Inc. price-consensus-chart | Apple Inc. Quote
Apple’s shares gained 11.5% over the last one month more than S&P 500’s gain of 3%. The company possesses a Momentum Score of A.
Apple Inc. Price
Apple Inc. price | Apple Inc. Quote
Adaptimmune Therapeutics plc : This clinical-stage biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.6% over the last 60 days.
Adaptimmune Therapeutics PLC Price and Consensus
Adaptimmune Therapeutics PLC price-consensus-chart | Adaptimmune Therapeutics PLC Quote
Adaptimmune Therapeutics’ shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
Adaptimmune Therapeutics PLC Price
Adaptimmune Therapeutics PLC price | Adaptimmune Therapeutics PLC Quote
AssetMark Financial Holdings, Inc. (AMK - Free Report) : This operator of wealth management and technology solutions has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.6% over the last 60 days.
AssetMark Financial Holdings, Inc. Price and Consensus
AssetMark Financial Holdings, Inc. price-consensus-chart | AssetMark Financial Holdings, Inc. Quote
AssetMark Financial’s shares gained 3.6% over the last one month. The company possesses a Momentum Score of A.
AssetMark Financial Holdings, Inc. Price
AssetMark Financial Holdings, Inc. price | AssetMark Financial Holdings, Inc. Quote
Cardlytics, Inc. (CDLX - Free Report) : This operator of a purchase intelligence platform has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
Cardlytics, Inc. Price and Consensus
Cardlytics, Inc. price-consensus-chart | Cardlytics, Inc. Quote
Cardlytics’ shares gained 40.6% over the last one month. The company possesses a Momentum Score of A.
Cardlytics, Inc. Price
Cardlytics, Inc. price | Cardlytics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>